5-HTP : 入眠困難
D 研究 予備的な研究(実験室研究、症例報告)のみが存在します。7件の研究に基づく。7件中7件の研究で肯定的な効果が示されている。
結論
There is not yet enough human research to confirm that 5-HTP helps you fall asleep faster, though early animal research is encouraging.
- All 7 studies are animal or preclinical studies with no human trial data
- Evidence grade is D, indicating very limited evidence
- 5-HTP works through the serotonin system, which plays a role in sleep onset
- Human clinical trials are needed before recommendations can be made
Key Study Findings
Key Statistics
7
研究数
--
参加者数
Positive
グレード
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- sleep:
- 100-300 mg, 30-45 min before bed
上限量: Not established; serotonin syndrome risk with SSRIs
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| Cinnamic acid (CA) administered to rats (dose not specified) | -- | Positive | -- |
| up to 96 mg/kg | -- | Positive | -- |
| not fully specified (dose ranges tested in Drosophila, ICR mice, and SD rats) | -- | Positive | -- |
| various doses; pentobarbital 50 mg/kg (full dose) or 28 mg/kg (sub-hypnotic dose) IP | -- | Positive | -- |
| 5-45 mg/kg i.p. schizandrin | -- | Positive | -- |
| Spinosin various doses; pentobarbital 45 mg/kg or 28 mg/kg i.p.; 5-HTP 2.5 mg/kg i.p.; PCPA 300 mg/k | -- | Positive | -- |
推奨摂取タイミング: 30-45 minutes before bed
Safety & Side Effects
報告されている副作用
- ⚠ Nausea
- ⚠ Diarrhea
- ⚠ Heartburn
- ⚠ Stomach pain
- ⚠ Drowsiness
既知の相互作用
- ● SSRIs/SNRIs — serious risk of serotonin syndrome
- ● MAOIs — dangerous serotonin accumulation
- ● Tramadol — increased serotonin syndrome risk
- ● Carbidopa — may cause scleroderma-like skin changes
耐容上限摂取量: Not established; serotonin syndrome risk with SSRIs
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does 5-HTP help with 入眠困難?
How much 5-HTP should I take for 入眠困難?
Are there side effects of 5-HTP?
How strong is the evidence for 5-HTP and 入眠困難?
Related Evidence
References
- [1] Jingyi Li et al.. Psychopharmacology (Berl). 2025. Ginsenoside Rg1 alleviates PCPA-induced insomnia by inhibiting NLRP3 inflammasome activation and pyroptosis through the Nrf2/HO-1 pathway in mice. doi:10.1007/s00213-025-06828-5 PubMed
- [2] Xiaona Ye et al.. Int Immunopharmacol. 2025. Promotion of sleep by cinnamic acid in parachlorophenylalanine-induced insomnia in rats. doi:10.1016/j.intimp.2025.114852 PubMed
- [3] Ning Mou et al.. RSC Adv. 2019. Study on the hypnotic effect of rare protopanaxadiol-type and protopanaxatriol-type ginsenosides. doi:10.1039/c9ra01549c PubMed
- [4] Ki-Bae Hong et al.. Nutr Res Pract. 2018. Two combined amino acids promote sleep activity in caffeine-induced sleepless model systems. doi:10.4162/nrp.2018.12.3.208 PubMed
- [5] Meng-Fei Ye et al.. Biomed Rep. 2015. Flos Albiziae aqueous extract and its active constituent quercetin potentiate the hypnotic effect of pentobarbital via the serotonergic system. doi:10.3892/br.2015.518 PubMed
- [6] Chenning Zhang et al.. Eur J Pharmacol. 2014. Pharmacological evaluation of sedative and hypnotic effects of schizandrin through the modification of pentobarbital-induced sleep behaviors in mice. doi:10.1016/j.ejphar.2014.09.012 PubMed
- [7] Li-En Wang et al.. Pharmacol Biochem Behav. 2008. Spinosin, a C-glycoside flavonoid from semen Zizhiphi Spinozae, potentiated pentobarbital-induced sleep via the serotonergic system. doi:10.1016/j.pbb.2008.03.022 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。